Annie Lamont: $14B Managed, 70+ Exits, 15 IPOs, 7x Midas Investor
Annie Lamont argues AI has reached the point of real impact in drug discovery and healthcare, that founder quality and defensibility matter more than hype, and that most inflated AI valuations won't hold.
Watch on YouTube ↗Charlie's summary
- ▶ 2:09
Oak's healthcare-plus-fintech focus covers about 50% of the economy, and deep buyer relationships help horizontal AI companies sell in.
Annie says Oak has invested in horizontal platforms that apply to both sectors, such as supply chain, risk, cyber and fraud. Healthcare is hard to sell into, but she calls it “the smallest large market you've ever seen”: about 100 providers that matter and 10 large payers. Knowing the buying motion and the people gives portfolio companies a real edge.
- ▶ 4:20
AI drug discovery finally works after a decade of disappointment, and Chai Discovery is the example.
Annie says Oak looked at AI for a decade and didn't see it produce more developable therapeutics; “everything's changed the last two years.” Biology and chemistry models, which are not LLMs, now sit on top of LLM-era infrastructure. She says Chai's antibody work makes it “a hundred times more productive than a lab without them,” with peptides next and then small molecules. Simulation can approximate results from wet-lab and animal models, provided the outputs are tested.
- ▶ 7:08
China's rise in life sciences is an existential threat, and cutting university research funding makes it worse.
Annie says pharma now sends 50% of its outside research dollars to China, which was not the case five years ago. She argues China has as many or more research patents as the US, so dismissing its work as me too drugs is wrong. She fears NIH funding cuts to universities, the bedrock of US discovery, will hurt the drug pipeline in the future, and she calls for a re-engineering of the FDA.
- ▶ 13:36
Devoted Health shows that defensibility, not just growth speed, is what makes an AI company hard to beat.
Annie says Devoted spent 10 years building a Medicare Advantage plan: licenses and provider networks in every state, its own technology platform, and its own primary care group. Adding AI while owning the risk and the member makes it “almost impossible to compete against.” It tripled in size last year and sharply raised EBITDA. She calls it probably the best example of AI applied to healthcare in the world.
Give your email to unlock the rest of the key points — for every episode.
Do more with Charlie
Free — sign in with your email, no password.